Sterling Pharma Solutions Limited

Sterling Pharma Solutions Limited

Sterling Pharma Solutions, based in Cramlington, Northumberland, is a pharmaceutical contract development and manufacturing organization (CDMO). It specializes in small-molecule active pharmaceutical ingredients (APIs) and intermediates, serving innovator and generic drug companies worldwide. The firm's precise founding year is not publicly detailed in available records. The company covers the pharmaceutical value chain from process development and analytical services through clinical-scale and commercial-scale manufacturing. It serves customers in Europe, North America, and other regulated markets. Sterling Pharma Solutions focuses on complex synthesis, including high-potency APIs, and operates facilities that adhere to Good Manufacturing Practice (GMP) standards. Its client list and specific portfolio companies are not publicly named in the available record. Sterling Pharma Solutions employs a workforce scientists and technicians on its Cramlington site. The company operates a single facility; no additional offices are documented in public sources. In recent years, it has made capital investments to expand capacity, though exact dates and amounts are not available in the consulted sources. Structurally, Sterling Pharma Solutions operates as a specialized, mid-cap CDMO rather than a private investment vehicle. It relies on a single-site, one-facility production model, which differentiates it from larger multinational CDMOs with global footprints. This operational structure indicates a focused manufacturing strategy.